WORLDWIDE APPROVAL
TIVICAY 50mg Tablets

Albania
Argentina
Armenia
Aruba
Australia
Azerbaijan
Bahrain
Bangladesh
Belarus
Bosnia and Herzegovina
Botswana
Brazil
Burkina Faso
Cameroon
Canada
Central Africa Republic
Chad
Chile
China
Colombia
Congo
Costa Rica
Cote D’Ivoire
Curacao
Democratic Republic of Congo
Dominican Republic
Ecuador
Egypt
El Salvador
Ethiopia
European Union
Gabon
Georgia
Ghana
Guatemala
Guinea
Guyana
Haiti
Honduras
Hong Kong
Indonesia
Israel
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kuwait
Kyrgyzstan
Lebanon
Liberia
Macau
Macedonia
Malawi
Malaysia
Mali
Mauritius
Mexico
Moldova
Mongolia
Montenegro
Morocco
Mozambique
Myanmar
Namibia
New Zealand
Nicaragua
Niger
Nigeria
Oman
Pakistan
Panama
Peru
Philippines
Qatar
Russian Federation
Saudi Arabia
Senegal
Serbia
Sierra Leone
Singapore
South Africa
South Korea
Suriname
Switzerland
Taiwan
Tanzania
Thailand
Togo
Trinidad and Tobago
Turkey
Uganda
Ukraine
United Arab Emirates
United States of America
Uruguay
Uzbekistan
Zambia
Zimbabwe

✓ “Approval” means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 12 July 2019 and will be updated on a quarterly basis by Viiv Healthcare. It is made available for information purposes only and Viiv Healthcare accepts no liability arising from the reliance by third parties on the information provided.